ONC201 and ONC206 Efficacy in Brain Tumors to be Presented at 2020 SNO Conference

Philadelphia, PA (November 11, 2020) – Oncoceutics, Inc. announced that the latest research on imipridones ONC201 and ONC206 for the treatment of brain tumors will be presented at the 2020 Society of Neuro-Oncology Virtual Annual Meeting to be held November 19th-21st.

These data will highlight clinical and translational findings over the past year, including:

  • Updated interim efficacy results for the ONC201 registration cohort in recurrent H3 K27M-mutant gliomas
  • Clinical safety, pharmacokinetics, and clinical outcomes for ONC201 in H3 K27M-mutant gliomas
  • Mechanism of action studies of ONC201 revealing new aspects of how it uniquely acts against brain tumors
  • Biodistribution and metabolism studies of ONC201, highlighting that ONC201 is distributed throughout targeted brain substructures
  • IND-enabling studies, predictive biomarkers and first-in-human trial design for ONC206
  • Distinctions between the potency, target engagement, and resistance mechanisms for ONC201 and ONC206
  • Preclinical efficacy and mechanism of action of ONC206 alone and in combination with other treatments, including ONC201, in specific brain tumors

Summaries and presentation information are provided below:

Format

Abstract/Title

Presenter

ONC201: Clinical

Oral

Efficacy of ONC201 in patients with recurrent H3 K27M-mutant diffuse midline glioma

Dr.  Isabel Arrillaga-Romany, MD, PhD, Massachusetts General Hospital  

Oral

Clinical efficacy of ONC201 in newly diagnosed DIPG and in previously irradiated pediatric H3 K27M-mutant gliomas

Sharon L. Gardner, MD, New York University

Oral

Clinical efficacy of ONC201 in H3 K27M-mutant diffuse midline glioma requires EGFR/FOXG1 independence

Abed Kawakibi, University of Michigan

ONC201: Preclinical

Oral

Cellular stress response in DIPG therapy

Vidya Gopalakrishnan, PhD,  M.D. Anderson Cancer Center

Poster

CYP450 and metabolic profiling of anti-cancer imipridone ONC201

Sara Morrow, Oncoceutics

Poster

ONC201 exhibits passive diffusion and broad distribution in the central nervous system

Sara Morrow, Oncoceutics

ONC206

Oral

IND-enabling characterization of dual DRD2- and ClpP-targeting agent ONC206 as the next imipridone for clinical neuro-oncology

Varun V. Prabhu, PhD, Oncoceutics

Poster

Preclinical efficacy of the imipridone ONC206 against medulloblastoma

Tobey J. MacDonald, MD, Emory University

Poster

Molecular differentiation of imipridones ONC201 and ONC206

Varun V. Prabhu, PhD Oncoceutics

Poster

Biomarker evaluation for imipridone ONC206 reveals ClpP, ATF4, MYC, EGFR and HIF1 as key predictors of anti-cancer efficacy

Sara Morrow, Oncoceutics

Combinatorial Efficacy: Preclinical

Poster

Synergistic tumor suppression from combination of ONC201 and epigenetic modulators EZH2 or HDAC inhibitor provides a novel treatment strategy for GBM and DMG

Wafik El-Deiry, MD, PhD, Brown University

Poster

International preclinical drug discovery and biomarker program informing an adoptive combinatorial trial for diffuse midline gliomas

Javad Nazarian, PhD, University Children’s Hospital Zurich

 
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. ONC201 is an orally active small molecule DRD2 antagonist and ClpP agonist in late-stage clinical development for H3 K27M-mutant glioma with additional indications under clinical investigation. ONC206 is the second clinical-stage imipridone that is under clinical investigation for central nervous system tumors. The company is supported by grants from NCI, FDA, The Musella Foundation, and the National Brain Tumor Society, and a series of private and public partnerships. Visit Oncoceutics.com for more information.

ONC201 and ONC206 Efficacy in Brain Tumors to be Presented at 2020 SNO Conference

ONC201 and ONC206 Efficacy in Brain Tumors to be Presented at 2020 SNO Conference

User Photo
alexvarney

1 week
13 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
>